Literature DB >> 22996046

Evidence for the involvement of the serotonergic 5-HT(1A) receptors in the antidepressant-like effect caused by hesperidin in mice.

Leandro C Souza1, Marcelo G de Gomes, André T R Goes, Lucian Del Fabbro, Carlos B Filho, Silvana P Boeira, Cristiano R Jesse.   

Abstract

The present study investigated a possible antidepressant-like activity of hesperidin using two predictive tests for antidepressant effect in mice: the forced swimming test (FST) and the tail suspension test (TST). Results demonstrated that hesperidin (0.1, 0.3 and 1 mg/kg, intraperitoneal, i.p.) decreased the immobility time in the FST and TST without affecting the locomotor activity in the open field test. The antidepressant-like effect of hesperidin (0.3 mg/kg) on the TST was prevented by the pretreatment of mice with p-chlorophenylalanine methyl ester (pCPA; 100 mg/kg, i.p., an inhibitor of serotonin synthesis) and WAY100635 (0.1 mg/kg, subcutaneous, s.c., a selective 5-HT(1A) receptor antagonist). Pretreatment of mice with prazosin (1 mg/kg, i.p., an α(1)-adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an α(2)-adrenoceptor antagonist), propranolol (2 mg/kg, i.p., a β-adrenoceptor antagonist), AMPT (100 mg/kg, i.p., an inhibitor of tyrosine hydroxylase), SCH23390 (0.05 mg/kg, s.c., a dopamine D(1) receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D(2) receptor antagonist), ketanserin (1mg/kg, i.p., a 5-HT(2A/2C) receptor antagonist) or MDL72222 (1 mg/kg, i.p., a 5-HT(3) receptor antagonist) did not block the antidepressant-like effect of hesperidin (0.3 mg/kg, i.p.) in the TST. Administration of hesperidin (0.01 mg/kg, i.p.) and fluoxetine (1 mg/kg), at subeffective doses, produced an antidepressant-like effect in the TST. The antidepressant-like effect caused by hesperidin in mice in the TST was dependent on an interaction with the serotonergic 5-HT(1A) receptors. Taken together, these results suggest that hesperidin possesses antidepressant-like property and may be of interest source for therapeutic agent for the treatment of depressive disorders. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996046     DOI: 10.1016/j.pnpbp.2012.09.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  27 in total

1.  Antidepressant-like activity of Tagetes lucida Cav. is mediated by 5-HT(1A) and 5-HT(2A) receptors.

Authors:  H Bonilla-Jaime; G Guadarrama-Cruz; F J Alarcon-Aguilar; O Limón-Morales; G Vazquez-Palacios
Journal:  J Nat Med       Date:  2015-06-11       Impact factor: 2.343

2.  Antidepressant, antioxidant and neurotrophic properties of the standardized extract of Cocos nucifera husk fiber in mice.

Authors:  Eliane Brito Cortez Lima; Caren Nádia Soares de Sousa; Germana Silva Vasconcelos; Lucas Nascimento Meneses; Yuri Freitas E Silva Pereira; Naiara Coelho Ximenes; Manuel Alves Santos Júnior; Natália Castelo Branco Matos; Rayanne Brito; Diogo Miron; Luzia Kalyne Almeida Moreira Leal; Danielle Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  J Nat Med       Date:  2016-02-08       Impact factor: 2.343

Review 3.  An ethnopharmacological review on the therapeutical properties of flavonoids and their mechanisms of actions: A comprehensive review based on up to date knowledge.

Authors:  Doha H Abou Baker
Journal:  Toxicol Rep       Date:  2022-03-14

Review 4.  Bioavailability of Hesperidin and Its Aglycone Hesperetin-Compounds Found in Citrus Fruits as a Parameter Conditioning the Pro-Health Potential (Neuroprotective and Antidiabetic Activity)-Mini-Review.

Authors:  Kamil Wdowiak; Jarosław Walkowiak; Robert Pietrzak; Aleksandra Bazan-Woźniak; Judyta Cielecka-Piontek
Journal:  Nutrients       Date:  2022-06-26       Impact factor: 6.706

Review 5.  Natural Products for the Treatment of Post-stroke Depression.

Authors:  Chaoyou Fang; Zeyu Zhang; Houshi Xu; Yibo Liu; Xiaoyu Wang; Ling Yuan; Yuanzhi Xu; Zhengyang Zhu; Anke Zhang; Anwen Shao; Meiqing Lou
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

6.  Evidence for the Involvement of Potassium Channel Inhibition in the Antidepressant-Like Effects of Hesperidin in the Tail Suspension Test in Mice.

Authors:  Franciele Donato; Carlos Borges Filho; Renata Giacomeli; Elza Eliza Tenório Alvater; Lucian Del Fabbro; Michele da Silva Antunes; Marcelo Gomes de Gomes; André Tiago Rossito Goes; Leandro Cattelan Souza; Silvana Peterini Boeira; Cristiano Ricardo Jesse
Journal:  J Med Food       Date:  2015-02-03       Impact factor: 2.786

7.  Hesperidin Alleviates Lipopolysaccharide-Induced Neuroinflammation in Mice by Promoting the miRNA-132 Pathway.

Authors:  Min Li; Huanzhang Shao; Xia Zhang; Bingyu Qin
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

Review 8.  Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases.

Authors:  Esra Küpeli Akkol; Irem Tatlı Çankaya; Gökçe Şeker Karatoprak; Elif Carpar; Eduardo Sobarzo-Sánchez; Raffaele Capasso
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

9.  hesperidin induces paraptosis like cell death in hepatoblastoma, HepG2 Cells: involvement of ERK1/2 MAPK [corrected].

Authors:  Silvia Yumnam; Hyeon Soo Park; Mun Ki Kim; Arulkumar Nagappan; Gyeong Eun Hong; Ho Jeong Lee; Won Sup Lee; Eun Hee Kim; Jae Hyeon Cho; Sung Chul Shin; Gon Sup Kim
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

10.  Hesperetin ameliorates diabetes-associated anxiety and depression-like behaviors in rats via activating Nrf2/ARE pathway.

Authors:  Xia Zhu; Yu-Meng Zhang; Meng-Ya Zhang; Ya-Jing Chen; Yao-Wu Liu
Journal:  Metab Brain Dis       Date:  2021-07-17       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.